

November 25, 2024

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: PMV Pharmaceuticals, Inc.  
Registration Statement on Form S-3  
Filed November 20, 2024  
File No. 333-283349  
Acceleration Request  
Requested Date: Wednesday, November 27, 2024  
Requested Time: 4:30 P.M. Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, PMV Pharmaceuticals, Inc. (the “**Company**”) hereby requests that the above-referenced Registration Statement on Form S-3 (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.

*[Signature page follows]*

Sincerely,  
PMV PHARMACEUTICALS, INC.  
/s/ Michael Carulli  
\_\_\_\_\_  
Michael Carulli  
*Chief Financial Officer*

cc: Kenneth A. Clark, Tony Jeffries, and Megan J. Baier, Wilson Sonsini Goodrich & Rosati, P.C.